ATE189697T1 - Die hocheffiziente herstellung und isolierung von viruspartikeln - Google Patents

Die hocheffiziente herstellung und isolierung von viruspartikeln

Info

Publication number
ATE189697T1
ATE189697T1 AT95914170T AT95914170T ATE189697T1 AT E189697 T1 ATE189697 T1 AT E189697T1 AT 95914170 T AT95914170 T AT 95914170T AT 95914170 T AT95914170 T AT 95914170T AT E189697 T1 ATE189697 T1 AT E189697T1
Authority
AT
Austria
Prior art keywords
exchange resin
isolation
cells
highly efficient
virus particles
Prior art date
Application number
AT95914170T
Other languages
English (en)
Inventor
Christopher P Prior
David M Weber
Richard S Gore
James J Harter
Michael E Hrinda
Jonathan J Mitschelen
Thomas W Irish
Pierre M Bay
George C Tarr
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Application granted granted Critical
Publication of ATE189697T1 publication Critical patent/ATE189697T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95914170T 1994-03-22 1995-03-22 Die hocheffiziente herstellung und isolierung von viruspartikeln ATE189697T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21583394A 1994-03-22 1994-03-22
PCT/US1995/003668 WO1995025789A1 (en) 1994-03-22 1995-03-22 Highly efficient production and isolation of viral particles

Publications (1)

Publication Number Publication Date
ATE189697T1 true ATE189697T1 (de) 2000-02-15

Family

ID=22804586

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914170T ATE189697T1 (de) 1994-03-22 1995-03-22 Die hocheffiziente herstellung und isolierung von viruspartikeln

Country Status (12)

Country Link
US (2) US5661023A (de)
EP (1) EP0751988B1 (de)
JP (1) JP3313117B2 (de)
AT (1) ATE189697T1 (de)
AU (1) AU2127395A (de)
CA (1) CA2186034C (de)
DE (1) DE69515028T2 (de)
DK (1) DK0751988T3 (de)
ES (1) ES2141929T3 (de)
GR (1) GR3033268T3 (de)
PT (1) PT751988E (de)
WO (1) WO1995025789A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69515028T2 (de) * 1994-03-22 2000-06-29 The Immune Response Corp., Carlsbad Die hocheffiziente herstellung und isolierung von viruspartikeln
IL127692A0 (en) * 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
FR2750433B1 (fr) * 1996-07-01 1998-08-14 Rhone Poulenc Rorer Sa Procede de production d'adenovirus recombinants
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
DK1009808T3 (da) * 1997-09-05 2013-01-21 Genzyme Corp Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
AU1956299A (en) * 1998-01-12 1999-07-26 Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada A process for the isolation, recovery and purification of non-polar extractives
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DE10010342A1 (de) * 2000-03-06 2001-09-20 Merck Patent Gmbh Verfahren zur Abreicherung von Endotoxinen
SE0001132D0 (sv) * 2000-03-29 2000-03-29 Cavidi Tech Ab Method of concentrating and recovering a viral enzyme activity from biological samples
US20040101964A1 (en) * 2000-05-10 2004-05-27 Shigemitsu Takashima Method of preparing virus vector
AU2002236517A1 (en) 2000-11-29 2002-06-11 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
JP2004531530A (ja) * 2001-02-11 2004-10-14 アクヴァノヴァ・ジャーマン・ソリュービリセイト・テクノロジーズ・（アーゲーテー）・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 活性物質の濃縮物の製法および活性物質の濃縮物
DE10137515A1 (de) * 2001-07-26 2003-02-13 Diagnostikforschung Inst Verfahren zur Herstellung pharmazeutischer Zubereitungen
US20030031626A1 (en) * 2001-07-26 2003-02-13 Thomas Rheinlander Process for the production of pharmaceutical preparations
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
EP2353389B1 (de) * 2003-04-21 2015-11-04 Epeius Biotechnologies Corporation Zusammensetzungen zur Behandlung von Erkrankungen
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
AU2005305347A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
DK2307551T3 (en) 2008-06-18 2017-03-20 Oxford Biomedica (Uk) Ltd CLEANING RETROVIRAL VECTORS
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
CN103476399A (zh) 2011-04-18 2013-12-25 独立行政法人国立精神·神经医疗研究中心 药剂递送粒子及其制造方法
EP2811983B1 (de) 2012-09-17 2019-05-01 W.R. Grace & CO. - CONN. Trägermaterial in form funktionalisierter teilchen und verfahren zur herstellung und verwendung davon
EP2812091B1 (de) 2012-09-17 2021-03-10 W.R. Grace & CO. - CONN. Chromatographiemedien und -vorrichtungen
ES2887110T3 (es) 2014-01-16 2021-12-21 Grace W R & Co Medios para cromatografía de afinidad y dispositivos para cromatografía
PL3137209T3 (pl) 2014-05-02 2023-01-02 W.R. Grace & Co. - Conn. Funkcjonalizowany materiał nośnikowy i sposoby wytwarzania oraz stosowania funkcjonalizowanego materiału nośnikowego
KR102566292B1 (ko) 2015-06-05 2023-08-10 더블유.알. 그레이스 앤드 캄파니-콘. 흡착성 바이오프로세싱 정화제와 이의 제조 및 사용 방법
EP3714033A1 (de) 2017-11-22 2020-09-30 Corning Incorporated Perfusionsbioreaktorsystem und perfusionszellkulturverfahren
US11028124B2 (en) * 2018-05-07 2021-06-08 Repligen Corporation Methods, devices and systems for 3-stage filtration
WO2020214676A1 (en) * 2019-04-15 2020-10-22 Children's Hospital Medical Center Viral vector manufacturing methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509070A (en) * 1968-06-13 1970-04-28 American Home Prod Adsorbent for chromatographic purification of virus
US3655509A (en) * 1969-05-29 1972-04-11 Monsanto Co Process for the separation of virus from non-viral proteins
US3925152A (en) * 1971-06-18 1975-12-09 Exploaterings Ab Tbf Virus separation
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6151571A (ja) * 1984-08-21 1986-03-14 Nippon Seibutsu Kagaku Kenkyusho オ−エスキ−病診断用抗原の単離・精製法
WO1988009670A1 (en) * 1987-06-10 1988-12-15 The Immune Response Corporation, Inc. Prevention and treatment of retroviral disease
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
CA2077753C (en) * 1990-03-09 2000-02-29 Nancy L. Haigwood Purified gp120 composition retaining natural conformation
FR2661834B1 (fr) * 1990-05-09 1995-01-27 Merieux Inst Procede de fabrication d'immunogenes de retrovirus et de vaccins contre les infections retrovirales, notamment hiv, et immunogenes et vaccins obtenus.
WO1992010564A1 (en) * 1990-12-13 1992-06-25 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
DE69515028T2 (de) * 1994-03-22 2000-06-29 The Immune Response Corp., Carlsbad Die hocheffiziente herstellung und isolierung von viruspartikeln
JPH08195877A (ja) * 1995-01-18 1996-07-30 Canon Inc イメージセンサと画像処理回路

Also Published As

Publication number Publication date
WO1995025789A1 (en) 1995-09-28
DE69515028D1 (de) 2000-03-16
EP0751988A1 (de) 1997-01-08
US6080571A (en) 2000-06-27
PT751988E (pt) 2000-05-31
CA2186034A1 (en) 1995-09-28
DE69515028T2 (de) 2000-06-29
US5661023A (en) 1997-08-26
EP0751988B1 (de) 2000-02-09
JP3313117B2 (ja) 2002-08-12
JPH10500286A (ja) 1998-01-13
AU2127395A (en) 1995-10-09
EP0751988A4 (de) 1997-11-12
GR3033268T3 (en) 2000-09-29
CA2186034C (en) 2002-11-26
DK0751988T3 (da) 2000-06-26
ES2141929T3 (es) 2000-04-01

Similar Documents

Publication Publication Date Title
ATE189697T1 (de) Die hocheffiziente herstellung und isolierung von viruspartikeln
EP1394259A3 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
MX9701183A (es) Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.
DE69634904D1 (de) Negativstrand rna virus mit selbständiger replikationsaktivität
DE69835294D1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus-ähnlichen tielchen (vlps)
DK0923592T3 (da) Fremgangsmåder til rensning af nukleinsyrer
EP0630280A4 (de) Verfahren und vorrichtung zur entfernung von dna, viren und endotoxinen.
DE69638196D1 (de) Rekombinantes sendai-virus
WO1996013597A3 (en) Improved adenovirus and methods of use thereof
FR2465508B1 (fr) Membranes poreuses contenant du polyacrylonitrile modifie, pour l'ultrafiltration, procede de preparation de celles-ci et applications desdites membranes
DE60233061D1 (de) Alphavirus replikon-vektorsysteme
TR199901840T2 (xx) DNA'nın cross-flow-filtrasyonu ile temizlenmesi.
PT88178A (pt) Metodo para a purificacao de virus da hepatite a
NO931093L (no) Fremgangsmaate for fremstilling av rensede glykolipider ved membrana dskillelsesfremgangsmaaten
AU4440196A (en) The removal of viruses from protein solutions by ultrafiltration
DE69324645D1 (de) Verfahren zur Herstellung von Hepatitis Antigenen und Impfstoffen
ATE133709T1 (de) Peroxidase-gen von mikrobischem ursprung
CA2096888A1 (en) Process for the inactivation of viruses in preparations of proteins
DK78990A (da) Fremgangsmaade til rensning af ydre membran protein for haemophilus influenza
FI96864C (fi) Ei-terapeuttisesti käytettävä HIV:n glykoproteiini GP 160 ja menetelmä sen valmistamiseksi
CA2154854A1 (en) Immortalized lymphocytes for production of viral-free proteins
PT82505A (fr) Cellules hybrides productrices d'un antigene caracteristique du virus de l'hepatite b obtenu a partir d'hepatocytes et de cellules etablies de singe procede pour l'obtention de ces cellules hybrides et application de celles-ci a la production de l'ant-gene susdit
CA2236113A1 (en) Negative strand rna viral vector having autonomous replication capability
IT8022031A0 (it) Processo ed impianto per laproduzione di energia elettrica mediante osmosi attraverso membrane semipermeabili.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee